A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2006
10/24/2006	US7125905 Pyrrole substituted 2-indolinone protein kinase inhibitors
10/24/2006	US7125904 Cardiovascular disorders; hypotensive agents; congestive heart failure
10/24/2006	US7125900 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
10/24/2006	US7125898 Kinase inhibitors to mediate disease and as antiinflammatory agents
10/24/2006	US7125897 Slowing or arresting progression of plaque in blood systems treatment with statins and oxidation
10/24/2006	US7125895 Arylalkylamine compounds as chemokine receptor antagonists for therapy and prevention of diseases such as arthritis or rheumatic diseases
10/24/2006	US7125892 Aryl aniline β2 adrenergic receptor agonists
10/24/2006	US7125889 Administering mixtures of heterocyclic imines and anticoagulants such as heparin or aspirin, to reduce blood coagualtion in mammals
10/24/2006	US7125887 Pyrrolidine modulators of CCR5 chemokine receptor activity
10/24/2006	US7125883 alpha v beta 3 integrin receptor modulators; treating variety of diseases including cardiovascular disorders, retinopathy, strokes, cancer, osteoporosis, tumor metastasis, high blood pressure, psoriasis, antiviral, antimycotic, antiparasitic or antibacterial therapy; 1,2-dihydropyrimidin-2-one moiety
10/24/2006	US7125881 Use of pyrimidine—or triazine—2 carbonitiles for treating diseases associated with cysteine prostease activity and novel pyrimidine-2-carbonitile derivatives
10/24/2006	US7125878 For therapy and prophylaxis of cardiovascular diseases, diabetes, diabetes- associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders
10/24/2006	US7125877 Brain disorders; psychological disorders; central nervous system disorders; antidiabetic agents; hypotensive agents
10/24/2006	US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
10/24/2006	US7125866 Therapeutic applications of pro-apoptotic benzodiazepines
10/24/2006	US7125839 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism
10/24/2006	US7125837 Elastin-based compositions
10/24/2006	US7125714 Progenitor cell materials and methods
10/24/2006	US7125699 for treating solid tumours, macular degeneration, corneal rejection, psoriasis, rheumatoid arthritis and chronic ulceration, and diseases involving vascular insufficiency, including stroke and following heart attack
10/24/2006	US7125688 A feline hepatocyte growth factor gene and a 15 base pairs-deleted feline hepatocyte growth factor gene. These genes encode the following protein (a) or (b): a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4; and a protein
10/24/2006	US7125573 Preventive, alleviative or remedy for hypertension
10/24/2006	US7125555 Oral preparation containing seaweed for reduction of plaque and calculus
10/24/2006	US7125547 Poly(diallylamine)-based bile acid sequestrants
10/24/2006	CA2330904C Fosinopril sodium tablet formulation
10/24/2006	CA2264598C 1,2,3,4-tetrahydro-benzofuro[3,2-c]pyridine derivatives
10/24/2006	CA2249402C Benzopyran derivatives having leukotriene-antagonistic action
10/24/2006	CA2195663C Dihydrobenzofuranes
10/24/2006	CA2168023C Vasoconstrictive substituted aryloxyalkyl diamines
10/21/2006	CA2504643A1 Methods of upregulating the heme oxygenase/carbon monoxide (ho/co) pathway
10/19/2006	WO2006110887A2 Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
10/19/2006	WO2006110882A2 Hmgcoa reductase inhibitor codrugs and uses thereof
10/19/2006	WO2006110483A1 Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
10/19/2006	WO2006109867A1 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVE OR MEDICALLY ACCEPTABLE SALT THEREOF
10/19/2006	WO2006109846A1 Triazole derivative and the use thereof
10/19/2006	WO2006109817A1 1,4-substituted piperazine derivative
10/19/2006	WO2006109633A1 Substituted indole compound
10/19/2006	WO2006109170A2 Combination therapy for treatment of cardiovascular diseases and related conditions
10/19/2006	WO2006109058A1 New bicyclic angiotensin ii agonists
10/19/2006	WO2006109048A1 New tricyclic angiotensin ii agonists
10/19/2006	WO2006108837A1 Aminoalkyl-amidomethyl-substituted 2- (4-sulphonylamino) -3-hydroxy-3 , 4-dihydro-2h-cromen-6-yl derivatives and their use as potassium channel blockers
10/19/2006	WO2006108686A2 Bnp agonists
10/19/2006	WO2006108670A2 Use of cd25 antibodies in immunotherapy
10/19/2006	WO2006108229A1 Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
10/19/2006	WO2006049984A3 Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists
10/19/2006	US20060235265 Cardiac support device with anti-fibrosis coating
10/19/2006	US20060235239 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
10/19/2006	US20060235132 Method of preparing poly(vinyl pivalate) by low temperature suspension-polymerization of vinyl pivalate, and poly(vinyl pivalate) and poly(vinyl alcohol) prepared using same
10/19/2006	US20060235078 Use of triterpenes of given formula based on a picene ring structure; side effect reduction such as of insulin resistance over current antidiabetes agents
10/19/2006	US20060235072 Potassium channel opener
10/19/2006	US20060235054 e.g. 3-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)imidazole-2-thione; immunomodulating and cytokine-release-inhibiting action; antiinflammatory agent
10/19/2006	US20060235049 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders
10/19/2006	US20060235043 Antiviral Pyrazolopyridine Compounds
10/19/2006	US20060235026 Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists
10/19/2006	US20060235023 Inhibitors of macrophage migration inhibitory factor and methods for indentifying the same
10/19/2006	US20060235019 Substituted quinazolinone compounds
10/19/2006	US20060235002 Novel physiologically active substance
10/19/2006	US20060234957 Adiponectin expression promoter
10/19/2006	US20060234955 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
10/19/2006	US20060234942 Use of at least one $g(a)62 casein peptide with angiotensin i converting enzyme inhibiting activity for preparing medicines, food products and food complements
10/19/2006	US20060234937 Modulation of angiogenesis
10/19/2006	US20060234924 A kit for screening a compound or its salt that promotes or inhibits the activity of the proteins; drug screening for hyperlipemia, arteriosclerosis, genital, digestive, respiratory diseases, renal, pancreatic, central nerve, respiratory, inflammatory, rheumatoid diseases and diabetic neurosis
10/19/2006	US20060234916 Cardioprotective agent
10/19/2006	US20060234913 Orally administering insulin and delivery agent 4-[(4-chloro, 2-hydroxybenzoyl)amino]butanoic acid that facilitates the absorption of insulin from the gastrointestinal tract; diabetes mellitus; bioavailability comparable to injection; treating diabetes without the drawbacks of systemic hyperglycemia
10/19/2006	US20060234344 Protein kinases
10/19/2006	US20060234297 Screening method
10/19/2006	US20060233897 Agent for preventing, improving or treating hypertension
10/19/2006	US20060233890 Method for treating a mammal by administration of a compound having the ability to release CO
10/19/2006	US20060233877 Betaine compositions
10/19/2006	US20060233833 Novel uses of parapoxvirus preparations
10/19/2006	US20060233815 Agents for protection from neointimal formation in grafts comprising an nfkappab decoy
10/19/2006	US20060233804 IGF antagonist peptides
10/19/2006	US20060233799 Use of il-18 inhibitors for treatment and/or prevention of peripheral vascular diseases
10/19/2006	US20060233746 N-terminally chemically modified protein compositions and methods
10/19/2006	DE112004000712T5 Verfahren zur Herstellung von Amlodipinmesilat-Monohydrat A process for preparing amlodipine mesylate monohydrate
10/19/2006	DE102005017605A1 Substiuierte 2-Aminoalkylthio-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substiuierte 2-aminoalkylthio-benzimidazoles, process for their preparation and their use as medicaments
10/19/2006	DE102005016634A1 Neuartige Aza-Hetercyclen als Kinase-Inhibitoren Novel aza-heterocycles as kinase inhibitors
10/19/2006	CA2604797A1 New tricyclic angiotensin ii agonists
10/19/2006	CA2604493A1 Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
10/19/2006	CA2604356A1 Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-yl derivatives and their use as potassium channel blockers
10/19/2006	CA2603701A1 1,4-substituted piperazine derivative
10/19/2006	CA2603457A1 Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
10/19/2006	CA2603402A1 Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
10/19/2006	CA2603254A1 New bicyclic angiotensin ii agonists
10/19/2006	CA2600709A1 Use of cd25 antibodies in immunotherapy
10/18/2006	EP1712548A2 5-amino-4-hydroxy-7-(pyridinylmethyl)-alkanamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
10/18/2006	EP1712239A2 Interleukin-1 inhibitors in the treatment of diseases
10/18/2006	EP1712221A1 Support accumulating in injured part in vascular channel
10/18/2006	EP1711459A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
10/18/2006	EP1711457A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
10/18/2006	EP1711203A1 Targeted atherosclerosis treatment
10/18/2006	EP1711177A1 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS
10/18/2006	EP1711168A2 Oral pharmaceutical compositions of candesartan cilexetil
10/18/2006	EP1641421A4 Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
10/18/2006	EP1345932B1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
10/18/2006	EP1339714B1 Novel sulfonamide-substituted pyrazolopyridine derivatives
10/18/2006	EP1283828B1 Novel polymorph v of torasemide
10/18/2006	EP1107957B1 Pyrimidine compounds
10/18/2006	EP1042468B1 Low-voltage activated calcium channel compositions and methods
10/18/2006	CN1849400A Polynucleotides and polypeptides of the erythropoietin gene
10/18/2006	CN1849317A Crystal of heterocyclic compound

1 ... 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 ... 1595